VER-01 Shows Enhanced Gastrointestinal Tolerability, Superior Pain Relief, and Improved Sleep Quality Compared to Opioids in Treating Chronic Low Back Pain: A Randomized Phase 3 Clinical Trial.

Also, while the difference in pain reduction between VER-01 and opioids did not reach statistical significance at week 27, longitudinal analysis across the entire 6-month treatment period demonstrated that VER-01 provided consistently greater symptom relief compared to opioids, reinforcing its therapeutic value beyond a single time-point assessment.

also in 111,027 other papers

Despite this limitation, the primary outcome of this trial was highly significant, underlining the markedly improved tolerability of VER-01 in comparison to opioids.

also in 132,142 other papers